Shenzhen-based medical device maker Edge Medical (HKEX: 02675) disclosed a share repurchase on 4 September 2026, acquiring 24,000 H-shares on the Hong Kong Stock Exchange for HKD 815,386. The on-market purchases were executed within a price range of HKD 33.66–34.00 per share, translating into a volume-weighted average cost of HKD 33.97.
Following the transaction, Edge Medical’s outstanding share count (excluding treasury shares) fell 0.0074% to 325.50 million. Treasury shares increased from 2.24 million to 2.26 million, while total issued shares remained unchanged at 327.76 million.
The buyback was conducted under a mandate approved by shareholders on 25 June 2026, which authorises repurchases of up to 32.61 million shares. After including the latest purchase, cumulative buybacks under this mandate stand at 647,200 shares, equal to 0.20% of the company’s issued share base at the mandate date—leaving approximately 31.97 million shares, or 97.0% of the authorised limit, still available.
Edge Medical affirmed that all repurchases complied with Hong Kong Listing Rules and that the acquired shares are being held in treasury; none have been cancelled. In line with regulatory requirements, the company is subject to a moratorium on issuing new shares or selling treasury shares until 4 October 2026.
Comments